Patents by Inventor Kalindi Parmar

Kalindi Parmar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS OF TREATING FANCONI ANEMIA
    Publication number: 20240000823
    Abstract: The present invention provides methods of treating, preventing or delaying the onset of bone marrow failure in Fanconi Anemia patients
    Type: Application
    Filed: July 20, 2023
    Publication date: January 4, 2024
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Alan D'Andrea, Kalindi Parmar, Haojian Zhang
  • Compositions and methods of treating Fanconi Anemia
    Patent number: 11707481
    Abstract: The present invention provides methods of treating, preventing or delaying the onset of bone marrow failure in Fanconi Anemia patients.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: July 25, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Alan D'Andrea, Kalindi Parmar, Haojian Zhang
  • Anti-TGF-beta antibody for the treatment of fanconi anemia
    Patent number: 10526402
    Abstract: The present invention provides methods of treating, preventing or delaying the onset of bone marrow failure in Fanconi Anemia patients comprising administering to the patient a composition comprising a neutralizing anti-TGF-beta antibody, e.g. fresolimumab or 1D11.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: January 7, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Alan D'Andrea, Kalindi Parmar, Haojian Zhang
  • Compounds and methods for treating cancer
    Patent number: 10450281
    Abstract: Provided are small molecule inhibitors of ubiquitin specific protease 2, 8 and 12 (USP2 and USP8 and USP12) activity and methods for their use in treating cancers. The small molecule inhibitors of the invention are particularly useful in the treatment of non-small cell lung cancers that are resistant to tyrosine kinase inhibitors and in the treatment of prostate cancer that is resistant to AR inhibitor therapy.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: October 22, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Alan D. D'Andrea, Nathanael S. Gray, Sara Jean Buhrlage, Kalindi Parmar
  • COMPOSITIONS AND METHODS OF TREATING FANCONI ANEMIA
    Publication number: 20180071330
    Abstract: The present invention provides methods of treating, preventing or delaying the onset of bone marrow failure in Fanconi Anemia patients.
    Type: Application
    Filed: February 26, 2016
    Publication date: March 15, 2018
    Inventors: Alan D'ANDREA, Kalindi PARMAR, Haojian ZHANG
  • ANTI-TGF-BETA ANTIBODY FOR THE TREATMENT OF FANCONI ANEMIA
    Publication number: 20180051075
    Abstract: The present invention provides methods of treating, preventing or delaying the onset of bone marrow failure in Fanconi Anemia patients comprising administering to the patient a composition comprising a neutralizing anti-TGF-beta antibody, e.g. fresolimumab or 1D11.
    Type: Application
    Filed: February 25, 2016
    Publication date: February 22, 2018
    Inventors: Alan D'ANDREA, Kalindi PARMAR, Haojian ZHANG
  • Compounds and methods for treating cancer
    Patent number: 9725425
    Abstract: Provided are small molecule inhibitors of ubiquitin specific protease 2, 8 and 12 (USP2 and USP8 and USP12) activity and methods for their use in treating cancers. The small molecule inhibitors of the invention are particularly useful in the treatment of non-small cell lung cancers that are resistant to tyrosine kinase inhibitors and in the treatment of prostate cancer that is resistant to AR inhibitor therapy.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: August 8, 2017
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Alan D. D'Andrea, Nathanael Gray, Sara Jean Buhrlage, Kalindi Parmar
  • Method for Selectively Depleting Hypoxic Cells
    Publication number: 20090136521
    Abstract: An improved method for selectively depleting hypoxic cells within the bone marrow is disclosed. The method can be used to enhance engraftment of hematopoietic stem cells (HSCs) in the bone marrow of a host subject. Also disclosed is a method for treating a cancer within the bone marrow of a host subject.
    Type: Application
    Filed: September 29, 2006
    Publication date: May 28, 2009
    Applicants: Genetix Pharmaceuticals , Inc., Dana-Farber Cancer Institute , Inc.
    Inventors: Kalindi Parmar, Peter Mauch, Julian Down